Skip to main content

How does Rybrevant work?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on Sep 23, 2021.

Official answer

by Drugs.com

Rybrevant works by targeting the epidermal growth factor receptor (EGFR) exon 20 insertion mutation and MET receptor found in adult patients with certain types of non-small cell lung cancer (NSCLC). EGFR and MET are proteins that helps cells to grow. Targeting these proteins helps to slow down cancer growth.

A mutation (change) in the gene for EGFR can make it grow too much and lead to cancer. This mutation is one change that your doctor may look for in NSCLC. Your doctor can perform a blood test (called a biomarker test) to make sure you have this mutation and can receive Rybrevant.

Rybrevant is used in patients with EGFR-positive NSCLC that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has not responded to platinum-based treatments.

How do I receive Rybrevant?

It is given as an intravenous (IV) infusion into your vein weekly for the first 4 weeks, then every 2 weeks, usually in an infusion clinic. The first dose is split into 2 infusions given over 2 consecutive days. Your doctor will monitor dose to treat infusion-related reactions if they should occur.

It is usually given until your disease worsens or you have side effects that require you to stop treatment.

Is Rybrevant chemotherapy?

No, Rybrevant (amivantamab-vmjw) is a targeted drug treatment known as a bispecific EGF receptor-directed and MET receptor-directed antibody used to treat certain types of non-small cell lung cancer with an EGFR gene mutation. Because it binds to two proteins, it’s called a "bispecific" monoclonal antibody. A monoclonal antibody is a lab-made version of a specific immune system protein.

It targets two proteins that help cancer cells grow: EGFR and MET. It is not considered a chemotherapy or an immunotherapy, but is a targeted drug that works specifically at these mutations.

How long does it work?

The answer to this question has not been fully answered because early-phase Rybrevant clinical studies are still ongoing.

In the ongoing Phase 1 CHRYSALIS study in 81 patients with NSCLC, the overall response rate was 40%, with 3.7% of patients having a complete response and 36% achieving a partial response. The median duration of response has lasted 11.1 months, with 63% of people having a duration of response lasting 6 months or longer.

Before you start treatment, discuss side effects with your doctor.

  • Rybrevant may cause serious side effects such as infusion-related reactions, interstitial lung disease / pneumonitis, skin reactions, and eye problems.
  • Common side effects include rash, musculoskeletal pain, shortness of breath, and nausea, among others.

Related: Rybrevant side effects (in more detail)

Continued approval for this use may depend upon verification and description of clinical benefit in Rybrevant confirmatory trials.

This is not all the information you need to know about Rybrevant (amivantamab-vmjw) for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full Rybrevant information here, and discuss this information and any questions you have with your doctor or other health care provider.

References

Related medical questions

Drug information

Related support groups